A National Hepatitis B and C Elimination Programme to Cut Bangladesh's Liver-Cancer Pipeline

Diagnosis

Hepatitis B and C are characterized in the curated note as a problem of chronic infection prevalence and as a driver of liver cancer. That framing matters because it identifies a slow, silent disease burden: most chronic carriers feel well for years while the virus quietly damages the liver, and the cost lands later as cirrhosis and liver cancer that are far more expensive and far less survivable than prevention. The note does not attach a current prevalence value (current_state is null), which is itself a finding: Bangladesh is managing a structural communicable-disease burden without a published, decision-grade surveillance number to steer it. You cannot eliminate what you do not count.

The disease structure favors action. Hepatitis B is preventable by vaccination, transmissible from mother to newborn, and suppressible with treatment. Hepatitis C is now curable with a short oral course. The binding gap is not the existence of tools but the absence of a coordinated programme that finds infections early, vaccinates newborns on time, and links the diagnosed to treatment. The lead body for that programme is the Directorate General of Health Services (DGHS).

Recommended actions

1. Stand up a national surveillance baseline. Owner: DGHS, through its disease-surveillance and laboratory network. Mechanism: a standardized chronic-hepatitis B/C testing and reporting protocol issued as a DGHS circular, with results aggregated centrally. Observable signal: a published, periodically updated national prevalence estimate replacing the current null, disaggregated by division.
2. Guarantee the hepatitis B birth dose. Owner: DGHS expanded-immunization machinery. Mechanism: a circular requiring a timely birth-dose hepatitis B vaccination at every delivery point, public and private, with cold-chain and stock accountability tied to facility reporting. Observable signal: rising share of newborns receiving an on-time birth dose, tracked monthly by facility.
3. Integrate screening into existing primary-care contact points. Owner: DGHS, with the Department of Public Health Engineering supporting safe-water and infection-control conditions at facilities. Mechanism: opt-out hepatitis B/C screening folded into antenatal visits, blood-donation, and routine outpatient registration, using a single national testing algorithm. Observable signal: number of people screened per month and the share of positives successfully referred.
4. Build a treat-and-cure pathway. Owner: DGHS, through designated district-level treatment sites. Mechanism: a procurement and distribution line for hepatitis B antivirals and a hepatitis C cure course, with a referral protocol from screening point to treatment site. Observable signal: number of diagnosed patients started on treatment and the share of hepatitis C patients completing a cure course.
5. Protect the blood and injection supply. Owner: DGHS, supported by the Department of Public Health Engineering on facility hygiene infrastructure. Mechanism: mandatory hepatitis B/C screening of all transfused blood and enforced single-use injection practice, audited by DGHS inspection. Observable signal: documented universal screening of transfused units and a falling count of unsafe-injection incidents.

Sequencing (first 12 months)

Start with surveillance and the birth dose, because they unlock everything else. The surveillance circular converts an unmeasured burden into a steerable number, which is what justifies budget and targets the high-prevalence divisions. The birth dose is the single highest-leverage prevention act and depends only on the existing immunization system, so it can move first. Once a baseline prevalence exists, layer in opt-out screening at primary-care contact points, then connect the diagnosed to a treatment pathway. Blood-supply and injection safety run in parallel from day one since they prevent new infections at near-zero marginal program cost.

Risks and constraints

The binding constraints are fiscal and operational, not scientific. A cure course and antivirals require a reliable procurement line, and any stockout breaks the trust that makes opt-out screening work. Surveillance demands laboratory capacity that is unevenly distributed, so the baseline will be weakest where the burden may be highest. Birth-dose timeliness depends on deliveries occurring inside the facility system; home deliveries are a structural leak. Politically, a silent disease competes poorly for attention against visible emergencies, so the programme must be anchored in a standing DGHS budget line rather than a one-off campaign.

Bottom line

Hepatitis B and C are a measurable, preventable, and largely treatable driver of liver cancer that Bangladesh is currently managing without a published prevalence number to steer by. DGHS should fix that first with a surveillance baseline and a guaranteed birth dose, then build the screen-and-treat pathway that turns a silent burden into an elimination target.